From the Journals: Progress Against Colorectal Cancer Lags in Three Large U.S. “Hot Spots”


While most of the United States has experienced large declines in colorectal cancer death rates in recent years, progress in three large “hot spots” has lagged, according to a study …

Read More

Overcoming Drug Resistance: The EGFR Enigma

EGFR square

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More